Bioventus Inc Stock Fair Value – BIOVENTUS INC Reports Q2 FY2023 Earnings Results on June 30 2023
August 13, 2023
🌥️Earnings Overview
BIOVENTUS INC ($NASDAQ:BVS) reported their second quarter earnings results for FY2023 on June 30 2023, with total revenue of USD 137.1 million, a decrease of 2.3% year-over-year. Net income showed an improvement from the previous year, at -3.7 million compared to -7.2 million in the same period of the prior year.
Market Price
BIOVENTUS INC, a healthcare company focused on developing and delivering orthobiologic solutions, reported its earnings results for the second quarter of FY2023 on June 30, 2023. Tuesday marked the opening of BIOVENTUS INC stock, starting at $3.9 and finishing the day with shares closing at $3.9, a surge of 14.1% from the prior day’s closing price of $3.4. The company’s financial performance was largely driven by strong growth in its orthobiologic products which saw a significant increase in quarterly sales compared to the same period last year.
Additionally, BIOVENTUS INC was able to offset rising expenses associated with its R&D investments by lowering operating costs and increasing revenue. Overall, BIOVENTUS INC’s Q2 FY2023 earnings results show a continuation of strong performance from the previous fiscal year. This reflects the company’s ability to develop and deliver innovative orthobiologic solutions that help patients to improve their mobility and quality of life. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bioventus Inc. More…
| Total Revenues | Net Income | Net Margin |
| 510.62 | -283.01 | 6.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bioventus Inc. More…
| Operations | Investing | Financing |
| 17.83 | -41.3 | 10.35 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bioventus Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 836.96 | 603.62 | 2.92 |
Key Ratios Snapshot
Some of the financial key ratios for Bioventus Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.6% | -8.4% | -58.2% |
| FCF Margin | ROE | ROA |
| 1.5% | -100.0% | -22.2% |
Analysis – Bioventus Inc Stock Fair Value
GoodWhale recently completed an analysis of BIOVENTUS INC‘s financials. Our proprietary Valuation Line allowed us to calculate the intrinsic value of BIOVENTUS INC share, which is around $9.1. Currently, BIOVENTUS INC stock is traded at $3.9, implying a discount of 57.3%. This indicates that BIOVENTUS INC shares are undervalued and presents a good opportunity for investors to purchase them at a discounted rate. More…
Peers
The market for bioventus is highly competitive with Motus GI Holdings Inc, Lucid Diagnostics Inc, Reshape Lifesciences Inc, all vying for a share of the pie. Bioventus Inc has a strong product portfolio and is well-positioned to compete in this market.
– Motus GI Holdings Inc ($NASDAQ:MOTS)
Motus GI Holdings Inc is a medical technology company that focuses on the development of endoscopic devices to provide gastrointestinal access and improve clinical outcomes. The company’s market cap as of 2022 is 5.93M and its ROE is -183.03%. Motus GI’s products are designed to provide superior clinical outcomes and improve patient safety by reducing procedural time, minimizing tissue trauma, and enhancing endoscopic visualization.
– Lucid Diagnostics Inc ($NASDAQ:LUCD)
Lucid Diagnostics Inc is a medical diagnostic company that develops and commercializes technology for the early detection of life-threatening diseases. The company’s products are based on the principle of detecting the presence of disease-specific antibodies in a patient’s blood. Lucid’s products are designed to provide accurate and reliable results within minutes, and are intended for use by both healthcare professionals and consumers. Lucid has a market cap of 71.74M as of 2022, a Return on Equity of -67.45%. The company’s products are based on the principle of detecting the presence of disease-specific antibodies in a patient’s blood. Lucid’s products are designed to provide accurate and reliable results within minutes, and are intended for use by both healthcare professionals and consumers.
– Reshape Lifesciences Inc ($NASDAQ:RSLS)
Reshape Lifesciences Inc is a biotechnology company that focuses on the development of therapies for the treatment of obesity and related diseases. The company has a market cap of 6.99M as of 2022 and a return on equity of -124.4%. Reshape Lifesciences Inc is headquartered in San Diego, California.
Summary
BIOVENTUS INC reported their second quarter earnings results for FY2023, with total revenue decreasing by 2.3% year-over-year to USD 137.1 million. Although they reported a net income loss of -3.7 million, it was an improvement from the -7.2 million reported in the same period of last year. Investor sentiment was positive, as the stock price moved up on the day of the announcement. Despite a decrease in revenue, BIOVENTUS INC’s improved net income reflected positively on investors, making it a potentially attractive investment option for those looking at the healthcare sector.
Related Posts
Recent Posts
